TTNP - התחייבויות לטווח ארוך של החברה titanpharm.com
Titan Pharmaceuticals (TTNP) develops innovative ProNeura implants for prolonged drug delivery, ensuring consistent therapy levels for addiction treatment. However, global market fragmentation and raw material supply disruptions are hindering exports and product output. This chart illustrates the company's long-term debt, which stands at 0.00. Business stability is supported by a strong team of developers and the recruitment of experts in clinical trial regulatory control.
Titan Pharmaceuticals, Inc. (TTNP) - פילוחי מדדים ודוחות פיננסיים
Long-term debt measures the volume of obligations with a maturity of more than one year, reflecting the borrowing strategy used to finance assets. The long-term debt time series for Titan Pharmaceuticals (TTNP) shows a current value of 0.00, which is critical during the restructuring of management at Titan Pharmaceuticals. The search for alternative revenue streams and the monetization of patents drive the dynamics of this metric. An increase in the credit load in the absence of operational efficiency raises default risks. A reduction in debt will signal the stabilization of financial sustainability.